EMPLOYMENT AGREEMENT (Alan L. Crane)Employment Agreement • March 11th, 2004 • Momenta Pharmaceuticals Inc • Massachusetts
EXHIBIT 10.21 CONSULTING AGREEMENT (Peter Barton Hutt) This Consulting Agreement (this "Agreement"), dated as of September 18, 2002 (the "Effective Date"), is made by and between Mimeon, Inc., a Delaware corporation (the "Company"), and Peter Barton...Consulting Agreement • March 11th, 2004 • Momenta Pharmaceuticals Inc • Massachusetts
EXHIBIT 10.37 FIRST LOAN MODIFICATION AGREEMENT This First Loan Modification Agreement (this "Loan Modification Agreement') is entered into as of December 28, 2004, by and between SILICON VALLEY BANK, a California-chartered bank, with its principal...Loan Modification Agreement • March 31st, 2005 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances)
EXHIBIT 4.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION...Warrant Agreement • March 11th, 2004 • Momenta Pharmaceuticals Inc • Massachusetts
SUBLEASESublease • March 11th, 2004 • Momenta Pharmaceuticals Inc
EXHIBIT 4.3 SECOND AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT This Second Amended and Restated Investors' Rights Agreement (this "Agreement") dated as of February 27, 2004 (this "Agreement") is made by and among Momenta Pharmaceuticals, Inc., a...Investors' Rights Agreement • June 15th, 2004 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Massachusetts
Shares Common StockUnderwriting Agreement • June 15th, 2004 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
EXHIBIT 10.15 EMPLOYMENT AGREEMENT (Susan Whoriskey) This Employment Agreement dated as of April 10, 2002 (this "Agreement") is made by and between Mimeon, Inc., a Delaware corporation (the "Company"), and Susan Whoriskey ("Employee"). WHEREAS,...Employment Agreement • March 11th, 2004 • Momenta Pharmaceuticals Inc
EXHIBIT 10.16 RESTRICTED STOCK PURCHASE AGREEMENT (Susan Whoriskey) This Restricted Stock Purchase Agreement dated as of April 10, 2002 (this "Agreement") is made by and between Mimeon, Inc., a Delaware corporation (the "Company"), and Susan Whoriskey...Restricted Stock Purchase Agreement • March 11th, 2004 • Momenta Pharmaceuticals Inc • Massachusetts
Momenta Pharmaceuticals, Inc. Common Stock, $0.0001 par value Underwriting AgreementUnderwriting Agreement • December 12th, 2019 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 14,516,130 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 2,177,419 additional shares (the “Optional Shares”) of Common Stock, par value $0.0001 (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
RIGHTS AGREEMENT between MOMENTA PHARMACEUTICALS, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY as Rights Agent Dated as of November 7, 2005Rights Agreement • November 8th, 2005 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
RIGHTS AGREEMENT, dated as of November 7, 2005 (the “Agreement”), between Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, as Rights Agent (the “Rights Agent”).
FORLicense Agreement • May 11th, 2004 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances)
1. PARTIES 68 Moulton Street Realty Trust, a (FILL IN) Massachusetts Trust with its mailing address of P.O. Box 95, Winchester, MA 01890. LESSOR, which expression shall include their heirs, successors, an assigns where the context so admits, does...Commercial Lease • March 11th, 2004 • Momenta Pharmaceuticals Inc
EXHIBIT 10.23 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (this "Agreement") dated as of December 27, 2002, between SILICON VALLEY BANK, a California chartered bank, with its principal place of business at 3003 Tasman Drive, Santa...Loan and Security Agreement • March 11th, 2004 • Momenta Pharmaceuticals Inc • Delaware
EXHIBIT 10.38 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this "Agreement") dated as of December 28, 2004, between SILICON VALLEY BANK, a California chartered bank, with its principal place of business at 3003 Tasman Drive, Santa...Loan and Security Agreement • March 31st, 2005 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
MOMENTA PHARMACEUTICALS, INC. 4,000,000 Shares Common Stock ($0.0001 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • December 9th, 2010 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
EXECUTION COPY CONFIDENTIAL MATERIALS OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS. COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • May 11th, 2004 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
MOMENTA PHARMACEUTICALS, INC. Common Stock ($0.0001 par value per share) AT- THE-MARKET EQUITY OFFERING SALES AGREEMENTAt-the-Market Equity Offering Sales Agreement • August 8th, 2019 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Stifel, Nicolaus & Company, Incorporated (“Stifel Nicolaus”), as sales agent and/or principal (“Agent”), shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), having an aggregate offering price of up to $100,000,000 on the terms set forth in Section 2 of this At-the-Market Equity Offering Sales Agreement (the “Agreement”). The Company agrees that whenever it determines to sell Shares directly to the Agent as principal, it will enter into a separate agreement (each, a “Terms Agreement”) in substantially the form of Annex I hereto, relating to such sale in accordance with Section 3 of this Agreement.
Underwriting AgreementUnderwriting Agreement • May 20th, 2015 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 7,250,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,087,500 additional shares (the “Optional Shares”) of Common Stock, par value $0.0001 (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
ANDExclusive Patent License Agreement • May 11th, 2004 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Massachusetts
MOMENTA PHARMACEUTICALS, INC. PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 12th, 2008 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Massachusetts
SUBSCRIPTION AGREEMENTSubscription Agreement • December 12th, 2008 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
The undersigned investor (the “Investor”) hereby confirms its agreement with Momenta Pharmaceuticals, Inc. (the “Company”) as follows:
AGREEMENT AND PLAN OF MERGER by and among JOHNSON & JOHNSON, VIGOR SUB, INC. and MOMENTA PHARMACEUTICALS, INC. Dated as of August 19, 2020Merger Agreement • August 19th, 2020 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of August 19, 2020 by and among JOHNSON & JOHNSON, a New Jersey corporation (“Parent”), VIGOR SUB, INC., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and MOMENTA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”).
MOMENTA PHARMACEUTICALS, INC. Executive Retention AgreementExecutive Retention Agreement • March 15th, 2007 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS EXECUTIVE RETENTION AGREEMENT by and between Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [ ] (the “Executive”) is effective as of the date of the last signature on the signature page attached hereto (the “Effective Date”).
August 19, 2020Retention Agreement • September 2nd, 2020 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Massachusetts
This letter agreement is in reference to the employment agreement between you and Momenta Pharmaceuticals, Inc. (the “Company”), dated as of April 28, 2008 (as amended through the date hereof, the “Employment Agreement”). As you know, Johnson & Johnson, a New Jersey corporation (“Parent”), Vigor Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of Parent (“Merger Sub”), and the Company propose to enter into a merger agreement (the “Merger Agreement”) that will (subject to the satisfaction of the terms and conditions of the Merger Agreement) result in Merger Sub being merged with and into the Company as a result of the Merger (as defined in the Merger Agreement) and the Company surviving the Merger as a wholly owned subsidiary of Parent. As a condition to the willingness of Parent and Merger Sub to enter into the Merger Agreement, Parent has requested that you enter into this letter agreement setting forth certain modifications to your rights and obligations under the
Exhibit 10.16 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. February 1, 2005 Dennis P. Bauer, Ph.D. Siegfried (USA), Inc. 33 Industrial Park Road Pennsville, NJ 08070 Dear...Development and Production Agreement • March 31st, 2005 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances)
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 3rd, 2019 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS EMPLOYMENT AGREEMENT (the "Agreement"), effective as of May 9, 2016, is entered into by Momenta Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 675 West Kendall Street, Cambridge, Massachusetts (the "Company"), and Anthony Manning, an individual residing at 185 Hancock Street, Apt 2, Cambridge, MA 02139 (the "Employee").
EMPLOYMENT AGREEMENTEmployment Agreement • September 2nd, 2020 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS EMPLOYMENT AGREEMENT (the “Agreement”), made this 28th day of April 2008, is entered into by Momenta Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 675 West Kendall Street, Cambridge, Massachusetts (the “Company”), and Ian Fier, an individual residing at the address indicated below (the “Employee”).
MOMENTA PHARMACEUTICALS, INC. Restricted Stock Agreement Granted Under 2004 Stock Incentive PlanRestricted Stock Agreement • November 8th, 2007 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
AGREEMENT made on August 15, 2007 between Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Richard P. Shea (the “Participant”).
EXHIBIT 10.11 RESTRICTED STOCK PURCHASE AGREEMENT (Alan L. Crane) This Restricted Stock Purchase Agreement dated as of March 15, 2002 (this "Agreement") is made by and between Mimeon, Inc., a Delaware corporation (the "Company"), and Alan L. Crane...Restricted Stock Purchase Agreement • March 11th, 2004 • Momenta Pharmaceuticals Inc • Massachusetts
EXHIBIT 10.22 RESTRICTED STOCK PURCHASE AGREEMENT (Peter Barton Hutt) This Restricted Stock Purchase Agreement dated as of June 13, 2001 (this "Agreement") is made by and between Mimeon, Inc., a Delaware corporation (the "Company"), and Peter Barton...Restricted Stock Purchase Agreement • March 11th, 2004 • Momenta Pharmaceuticals Inc • Massachusetts
Novartis Pharma AG AND Momenta Pharmaceuticals, Inc. INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • November 8th, 2006 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of July 25, 2006, by and between Novartis Pharma AG (the “Investor”), a corporation organized under the laws of Switzerland, with its principal place of business at Lichtstraße 35, CH 4058 Basel BS, and Momenta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with its principal place of business at 675 West Kendall Street, Cambridge, Massachusetts 02142.
MOMENTA PHARMACEUTICALS, INC. Restricted Stock Agreement Granted Under 2004 Stock Incentive PlanRestricted Stock Agreement • March 10th, 2008 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
AGREEMENT made on December 14, 2007 between Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and John Bishop (the “Participant”).
Novartis Pharma AG AND Momenta Pharmaceuticals, Inc. STOCK PURCHASE AGREEMENTStock Purchase Agreement • November 8th, 2006 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of July 25, 2006, by and between Novartis Pharma AG (the “Investor”), a corporation organized under the laws of Switzerland, with its principal place of business at Lichtstraße 35, CH 4058 Basel BS, and Momenta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with its principal place of business at 675 West Kendall Street, Cambridge, Massachusetts 02142.
FOURTH AMENDMENT TO SUBLEASESublease • July 18th, 2014 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS FOURTH AMENDMENT TO SUBLEASE (“Fourth Amendment”) is entered into as of the 14th day of July, 2014 by and between Vertex Pharmaceuticals Incorporated (“Sublandlord”) and Momenta Pharmaceuticals, Inc. (“Subtenant”).
